Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study

Background Although hypertension is the most common risk factor for atrial fibrillation (AF), whether blood pressure (BP) control varies across the spectrum of stroke risk in patients with AF or by adequacy of their thromboprophylaxis management is unclear. Methods We examined data from the RE-LY AF registry conducted at 164 emergency departments (EDs) in 47 countries between December 2007 and October 2011. Results Of the 15,400 patients in the registry, we analyzed the 9929 (mean age 67.5 years, 51.9% men) with a prior history of AF and complete BP data. While 6508 (66.5%) AF patients had hypertension, the prevalence varied widely depending on comorbidity profiles: from 45.4% in those without other cardiovascular risk factors to 82.5% in those with AF and diabetes. Although 93.9% of AF patients with hypertension were on at least one antihypertensive agent, fewer than half had BP levels ≤ 140/90 with no difference across risk profiles: 45.9% of those with NVAF and CHADS2 scores of 1 and 45.6% of those with NVAF and CHADS2 scores of 2 or more (46.9% and 45.3% for CHA2DS2-VASc scores of 1 versus 2 or more). BP control rates were not significantly better in those NVAF patients receiving guideline concordant thromboprophylaxis management (47.2%, aOR 1.03, 95%CI 0.89–1.20) than in those not receiving guideline-concordant antithrombotic therapy (45.3%). Conclusions Hypertension was common in patients with AF but BP control rates were sub-optimal and varied little across the spectrum of stroke risk or by adequacy of thromboprophylaxis. This highlights the need for an increased focus on total atherosclerotic risk rather than just thromboprophylaxis management in AF patients.

[1]  J. Healey,et al.  Although non-stroke outcomes are more common, stroke risk scores can be used for prediction in patients with atrial fibrillation. , 2018, International journal of cardiology.

[2]  Si‐Hyuck Kang,et al.  Long-term cardiovascular risk of hypertensive events in emergency department: A population-based 10-year follow-up study , 2018, PloS one.

[3]  Neha J. Pagidipati,et al.  Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin) , 2017, Circulation.

[4]  Neha J. Pagidipati,et al.  Abstract 086: Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes: International Insights From the TECOS Trial , 2017 .

[5]  Hynek Pikhart,et al.  Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants , 2017, The Lancet.

[6]  Jun Zhu,et al.  Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study , 2016, The Lancet.

[7]  Sally Hopewell,et al.  Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis , 2016, British Medical Journal.

[8]  B. Freedman,et al.  Residual Risk of Stroke and Death in Anticoagulant-Treated Patients With Atrial Fibrillation. , 2016, JAMA cardiology.

[9]  I. V. Van Gelder,et al.  Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries: The RE-LY Atrial Fibrillation Registry , 2014, Circulation.

[10]  F. McAlister,et al.  The impact of cardiovascular risk-factor profiles on blood pressure control rates in adults from Canada and the United States. , 2013, The Canadian journal of cardiology.

[11]  D. Belletti,et al.  Effect of cardiometabolic risk factors on hypertension management: a cross-sectional study among 28 physician practices in the United States , 2010, Cardiovascular diabetology.

[12]  T. Urech,et al.  Will Hypertension Performance Measures Used for Pay-for-Performance Programs Penalize Those Who Care for Medically Complex Patients? , 2009, Circulation.

[13]  S. Yusuf,et al.  Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range , 2008, Circulation.

[14]  C. Hollenbeak,et al.  Effect of Unrelated Comorbid Conditions on Hypertension Management , 2008, Annals of Internal Medicine.

[15]  R. Gillum,et al.  High blood pressure and cardiovascular disease mortality risk among U.S. adults: the third National Health and Nutrition Examination Survey mortality follow-up study. , 2008, Annals of epidemiology.

[16]  Gregory W Albers,et al.  Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. , 2007, Archives of internal medicine.

[17]  E. Hess,et al.  Clinical policy: critical issues in the evaluation and management of adult patients with asymptomatic hypertension in the emergency department. , 2006, Annals of emergency medicine.

[18]  Deepak L. Bhatt,et al.  International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. , 2006, JAMA.

[19]  G. Thorgeirsson,et al.  Risk profiles and prognosis of treated and untreated hypertensive men and women in a population-based longitudinal study The Reykjavik Study , 2004, Journal of Human Hypertension.

[20]  조남욱 전자/제조업의 Collaboration 전략 , 2003 .

[21]  L. Guize,et al.  Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population , 2003, Journal of hypertension.

[22]  L. Ackerson,et al.  Reproducibility of increased blood pressure during an emergency department or urgent care visit. , 2003, Annals of emergency medicine.

[23]  S. Straus,et al.  Measurement of blood presssure: an evidence based review , 2001, BMJ : British Medical Journal.

[24]  I D Graham,et al.  The management of hypertension in Canada: a review of current guidelines, their shortcomings and implications for the future. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[25]  A. Dyer,et al.  Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. , 1999, JAMA.

[26]  T. Hedner,et al.  Survival in treated hypertension: follow up study after two decades , 1998, BMJ.

[27]  N J Birkett,et al.  The effect of alternative criteria for hypertension on estimates of prevalence and control , 1997, Journal of hypertension.

[28]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.

[29]  K. Iserson,et al.  Use of the emergency department for hypertension screening: a prospective study. , 1987, Annals of emergency medicine.